India, Dec. 11 -- Today's Daily Dose brings you news about the FDA panel's vote on Correvio Pharma's anti-arrhythmic drug Brinavess; the near-term catalyst of Eloxx Pharma; the phase III trial results of Iterum's Sulopenem in the treatment of complicated intra-abdominal infections, and Xeris Pharma's phase II study results of ready-to-use (RTU) glucagon.

Read on.

Correvio Pharma Corp.'s (CORV)(CORV.TO) anti-arrhythmic drug Brinavess, proposed for the rapid conversion of recent onset atrial fibrillation in adult patients, has failed to win the backing of the FDA's Cardiovascular and Renal Drugs Advisory Committee.

The Committee jointly voted that the benefit-risk profile was not adequate to support approval. The FDA's final decision is ...